BFC
MIRM icon

Bedel Financial Consulting’s Mirum Pharmaceuticals MIRM Stock Holding History

Bedel Financial Consulting’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$2K – 1049
2021
Q3 		$2K Hold
100
– – ﹤0.01% 890
2021
Q2 		$2K Hold
100
– – ﹤0.01% 892
2021
Q1 		$2K Buy
+100
New +$1.91K ﹤0.01% 858

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bedel Financial Consulting's MIRM Position: Q4 2021 in Review

Bedel Financial Consulting sold out of Mirum Pharmaceuticals (MIRM) in Q4 2021, closing a stake of 100 shares — an estimated $2K sold.

Bedel Financial Consulting first reported a position in MIRM in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 86 funds tracked by Wall St. Rank hold MIRM as of Q4 2021.

  • Bedel Financial Consulting reported no remaining Mirum Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Bedel Financial Consulting sold 100 Mirum Pharmaceuticals shares in Q4 2021, an estimated $2K.
  • Bedel Financial Consulting first reported a position in Mirum Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Bedel Financial Consulting's Mirum Pharmaceuticals position peaked at $2K in Q3 2021.
  • 86 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2021.

Based on Bedel Financial Consulting's 13F filing for Q4 2021, filed 11 Jan 2022.